Literature DB >> 27574741

Lung cancer: current therapies and new targeted treatments.

Fred R Hirsch1, Giorgio V Scagliotti2, James L Mulshine3, Regina Kwon4, Walter J Curran5, Yi-Long Wu6, Luis Paz-Ares7.   

Abstract

Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million people die as a result of the disease. 5-year survival rates vary from 4-17% depending on stage and regional differences. In this Seminar, we discuss existing treatment for patients with lung cancer and the promise of precision medicine, with special emphasis on new targeted therapies. Some subgroups, eg-patients with poor performance status and elderly patients-are not specifically addressed, because these groups require special treatment considerations and no frameworks have been established in terms of new targeted therapies. We discuss prevention and early detection of lung cancer with an emphasis on lung cancer screening. Although we acknowledge the importance of smoking prevention and cessation, this is a large topic beyond the scope of this Seminar.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27574741     DOI: 10.1016/S0140-6736(16)30958-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  853 in total

1.  High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data.

Authors:  Mariacarmela Santarpia; Giuseppe Altavilla; Nicolo Borsellino; Andrea Girlando; Gianfranco Mancuso; Stefano Pergolizzi; Dario Piazza; Antonio Pontoriero; Maria Rosaria Valerio; Vittorio Gebbia
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.

Authors:  Yuma Shindo; Wataru Arai; Takumi Konno; Takayuki Kohno; Yuki Kodera; Hirofumi Chiba; Masahiro Miyajima; Yuji Sakuma; Atsushi Watanabe; Takashi Kojima
Journal:  Histochem Cell Biol       Date:  2021-05-11       Impact factor: 4.304

Review 3.  An American Thoracic Society/National Heart, Lung, and Blood Institute Workshop Report: Addressing Respiratory Health Equality in the United States.

Authors:  Juan C Celedón; Esteban G Burchard; Dean Schraufnagel; Carlos Castillo-Salgado; Marc Schenker; John Balmes; Enid Neptune; Kristin J Cummings; Fernando Holguin; Kristin A Riekert; Juan P Wisnivesky; Joe G N Garcia; Jesse Roman; Rick Kittles; Victor E Ortega; Susan Redline; Rasika Mathias; Al Thomas; Jonathan Samet; Jean G Ford
Journal:  Ann Am Thorac Soc       Date:  2017-05

4.  PDLIM5 inhibits STUB1-mediated degradation of SMAD3 and promotes the migration and invasion of lung cancer cells.

Authors:  Yueli Shi; Xinyu Wang; Zhiyong Xu; Ying He; Chunyi Guo; Lingjuan He; Caijuan Huan; Changhong Cai; Jiaqi Huang; Jie Zhang; Yiqing Li; Chunlai Zeng; Xue Zhang; Linrun Wang; Yuehai Ke; Hongqiang Cheng
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

5.  Leveraging the Power of Genetics to Bring Precision Medicine to Psychiatry: Too Little of a Good Thing?

Authors:  Daniel Moreno-De-Luca; Michael E Ross; David A Ross
Journal:  Biol Psychiatry       Date:  2018-04-15       Impact factor: 13.382

6.  New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy.

Authors:  Daniel C McFarland
Journal:  Gen Hosp Psychiatry       Date:  2019-04-18       Impact factor: 3.238

7.  The relationship between nutritional status and prognosis in patients with locally advanced and advanced stage lung cancer.

Authors:  Busra Gul; Selma Metintas; Guntulu Ak; Senay Yilmaz; Muzaffer Metintas
Journal:  Support Care Cancer       Date:  2020-10-30       Impact factor: 3.603

8.  6-Methoxyquinoline complexes as lung carcinoma agents: induction of oxidative damage on A549 monolayer and multicellular spheroid model.

Authors:  J F Cadavid-Vargas; C Villa-Pérez; M C Ruiz; I E León; G C Valencia-Uribe; D B Soria; S B Etcheverry; A L Di Virgilio
Journal:  J Biol Inorg Chem       Date:  2019-01-30       Impact factor: 3.358

9.  The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.

Authors:  Juan Wang; Shumei Ma; Xiuhua Chen; Sanqi Zhang; Zhiyong Wang; Qibing Mei
Journal:  Invest New Drugs       Date:  2018-11-19       Impact factor: 3.850

10.  Discovery of a Chiral DNA-Targeted Platinum-Acridine Agent with Potent Enantioselective Anticancer Activity.

Authors:  Shenjie Zhang; Xiyuan Yao; Noah H Watkins; P Keegan Rose; Sofia R Caruso; Cynthia S Day; Ulrich Bierbach
Journal:  Angew Chem Int Ed Engl       Date:  2020-09-29       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.